Statera Biopharma (STAB) 10-K 6 Mar 18 2017 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2017	Feb. 28, 2018	Jun. 30, 2017
Document And Entity Information [Abstract]
Entity Registrant Name	CLEVELAND BIOLABS INC
Trading Symbol	CBLI
Entity Central Index Key	1,318,641
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Document Type	10-K
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Common Stock, Shares Outstanding		11,279,834
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 13,886,205

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 4,230,548	$ 6,901,816
Short-term investments	4,561,357	8,343,657
Accounts receivable	554,468	352,700
Other current assets	233,617	289,768
Total current assets	9,579,990	15,887,941
Equipment, net	18,588	37,376
Other long-term assets	30,684	30,553
Total assets	9,629,262	15,955,870
Current liabilities:
Accounts payable	201,396	336,435
Accrued expenses	970,547	1,823,235
Accrued warrant liability	1,041,455	949,419
Total current liabilities	2,213,398	3,109,089
Non-current liabilities	7,494	0
Commitments and contingencies	0	0
Total liabilities	2,220,892	3,109,089
Stockholders’ equity:
Preferred stock, $.005 par value; 1,000,000 and 10,000,000 shares authorized as of December 31, 2017 and December 31, 2016, respectively, 0 shares issued and outstanding as of December 31, 2017 and December 31, 2016	0	0
Common stock, $.005 par value; 25,000,000 and 160,000,000 shares authorized as of December 31, 2017 and December 31, 2016, respectively, 11,279,834 and 10,987,166 shares issued and outstanding as of December 30, 2017 and December 31, 2016, respectively	56,395	54,932
Additional paid-in capital	163,106,400	158,773,753
Other comprehensive loss	(516,457)	(564,559)
Accumulated deficit	(160,446,612)	(150,740,156)
Total Cleveland BioLabs, Inc. stockholders’ equity	2,199,726	7,523,970
Noncontrolling interest in stockholders’ equity	5,208,644	5,322,811
Total stockholders’ equity	7,408,370	12,846,781
Total liabilities and stockholders’ equity	$ 9,629,262	$ 15,955,870

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Preferred stock, par value ($ per share)	$ 0.005	$ 0.005
Preferred stock, shares authorized	1,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value ($ per share)	$ 0.005	$ 0.005
Common stock, authorized (shares)	25,000,000	160,000,000
Common stock, issued (shares)	11,279,834	10,987,166
Common stock, outstanding (shares)	11,279,834	10,987,166
Treasury stock, (shares)	0	0

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Revenues:
Grants and contracts	$ 1,948,362	$ 3,518,402
Operating expenses:
Research and development	5,048,423	6,496,122
General and administrative	2,500,749	3,378,130
Total operating expenses	7,549,172	9,874,252
Loss from operations	(5,600,810)	(6,355,850)
Other income (expense):
Interest and other income	197,766	263,653
Foreign exchange gain (loss)	(13,482)	362,140
Gain on investment provision	0	40,517
Change in value of warrant liability	(4,426,146)	3,099,481
Total other income (expense)	(4,241,862)	3,765,791
Net loss	(9,842,672)	(2,590,059)
Net loss (gain) attributable to noncontrolling interests	136,216	(68,806)
Net loss attributable to Cleveland BioLabs, Inc.	$ (9,706,456)	$ (2,658,865)
Net income (loss) available to common stockholders per share of common stock, basic and diluted (per share)	$ (0.87)	$ (0.24)
Weighted average number of shares used in calculating net income (loss) per share, basic and diluted (shares)	11,192,435	10,987,166

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Statement of Comprehensive Income [Abstract]
Net loss including noncontrolling interests	$ (9,842,672)	$ (2,590,059)
Other comprehensive income (loss):
Unrealized gain on short-term investments	362	3,904
Foreign currency translation adjustment	69,789	(158,537)
Comprehensive loss including noncontrolling interests	(9,772,521)	(2,744,692)
Comprehensive loss (gain) attributable to noncontrolling interests	114,167	(63,448)
Comprehensive loss attributable to Cleveland BioLabs, Inc.	$ (9,658,354)	$ (2,808,140)

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Cash flows from operating activities:
Net loss	$ (9,842,672)	$ (2,590,059)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	21,081	63,456
Unrealized currency gain on short-term investments	(54,551)	(43,931)
Gain on equipment disposal	(6,727)	(180,901)
Investment loss provision	0	43,524
Non-cash compensation	0	13,623
Change in value of warrant liability	4,426,146	(3,099,481)
Changes in operating assets and liabilities:
Accounts receivable	(201,768)	300,762
Other current assets	57,325	174,717
Other long-term assets	0	(3,736)
Accounts payable	(138,578)	124,006
Deferred revenue	2,285	(12,929)
Accrued expenses	(874,000)	171,310
Net cash used in operating activities	(6,611,459)	(5,039,639)
Cash flows from investing activities:
Purchase of short-term investments	(8,631,685)	(17,225,557)
Sale of short-term investments	12,515,024	22,712,480
Proceeds from sale of equipment	8,956	198,914
Purchase of equipment	(4,404)	(10,249)
Decrease in restricted cash	0	(2,575)
Net cash provided by investing activities	3,887,891	5,673,013
Cash flows from financing activities:
Net proceeds from sale of treasury stock	0	539,998
Net cash provided by financing activities	0	539,998
Effect of exchange rate change on cash and equivalents	52,300	(189,980)
Increase (decrease) in cash and cash equivalents	(2,671,268)	983,392
Cash and cash equivalents at beginning of period	6,901,816	5,918,424
Cash and cash equivalents at end of period	4,230,548	6,901,816
Supplemental disclosure of cash flow information:
Cash paid during the period for interest	0	0
Supplemental schedule of non-cash financing activities:
Cashless exercise of warrants	$ 4,334,110	$ 0

CONSOLIDATED STATEMENT OF STOCK

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($)	Total	Common Stock	Treasury Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Noncontrolling Interests
Beginning balance (in shares) at Dec. 31, 2015		10,987,166	158,900
Beginning balance at Dec. 31, 2015	$ 15,037,852	$ 54,932	$ (544,853)	$ 158,764,985	$ (408,051)	$ (147,978,831)	$ 5,149,670
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock based compensation (in shares)		0
Stock based compensation	13,623	$ 0		13,623
Sale of Treasury Stock (in shares)			(158,900)
Sale of Treasury Stock	539,998		$ 544,853	(4,855)
Exercise of warrants	0
Increased ownership of Panacela Labs, Inc.	0			0	(7,233)	(102,460)	109,693
Net loss	(2,590,059)					(2,658,865)	68,806
Unrealized gain on short-term investments	3,904				3,904
Foreign currency translation	(158,537)				(153,179)		(5,358)
Ending balance (in shares) at Dec. 31, 2016		10,987,166	0
Ending balance at Dec. 31, 2016	12,846,781	$ 54,932	$ 0	158,773,753	(564,559)	(150,740,156)	5,322,811
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of warrants (in shares)		292,688
Exercise of warrants	4,334,110	$ 1,463		4,332,647
Net loss	(9,842,672)					(9,706,456)	(136,216)
Unrealized gain on short-term investments	362				362
Foreign currency translation	69,789				47,740		22,049
Ending balance (in shares) at Dec. 31, 2017		11,279,854	0
Ending balance at Dec. 31, 2017	$ 7,408,370	$ 56,395	$ 0	$ 163,106,400	$ (516,457)	$ (160,446,612)	$ 5,208,644

Description of Business

Description of Business	12 Months Ended
	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	Description of Business Cleveland BioLabs, Inc. (" CBLI " or the " Company ") is an innovative biopharmaceutical company developing novel approaches to activate the immune system and address serious medical needs. Our proprietary platform of Toll-like immune receptor ( "TLR" ) activators has applications in radiation protection and immuno-oncology. We combine our proven scientific expertise and our depth of knowledge about our products’ mechanisms of action into a passion for developing drugs to save lives. Our most advanced product candidate is entolimod, an immune-stimulatory agent, which we are developing as a medical radiation countermeasure and an immunotherapy for oncology and other indications. CBLI was incorporated in Delaware in June 2003 and is headquartered in Buffalo, New York. CBLI conducts business in the United States (" U.S. ") and in the Russian Federation (" Russia ") through two subsidiaries: one wholly owned subsidiary, BioLab 612, LLC ( "BioLab 612" ), which began operations in 2012; and Panacela Labs, Inc. (" Panacela "), which was formed by us and Joint Stock Company RUSNANO (" Rusnano "), our financial partner in the venture, in 2011. Unless otherwise noted, references to the "Company," "we," "us" and "our" refer to Cleveland BioLabs, Inc. together with its subsidiaries.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Basis of Presentation and Consolidation The accompanying consolidated financial statements include the accounts of CBLI, BioLab 612, and Panacela. All significant intercompany balances and transactions have been eliminated in consolidation. These financial statements have been prepared on the accrual basis in accordance with accounting principles generally accepted in the United States (" GAAP "). Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Cash and Cash Equivalents Of the $4.2 million and $6.9 million of cash and cash equivalents at December 31, 2017 and December 31, 2016 , respectively, $3.6 million and $2.4 million , respectively, consisted of highly liquid investments with maturities of 90 days or less when purchased. These investments consist of investments in money market funds with commercial banks and financial institutions. As of December 31, 2017 , $114,500 of the Company’s cash and cash equivalents were held in Russian banks, of which $111,600 was denominated in rubles with the remaining $2,900 denominated in U.S. dollars. Short-Term Investments The Company’s short-term investments are classified as available for sale and held to maturity. Short-term investments consisted of United States Treasury securities in the amount of $3.6 million which were owned by CBLI and had maturities of less than 12 months. Accordingly, these investments are carried at fair market value. In addition, $1.0 million in certificates of deposit with maturity dates beyond three months and less than one year, and owned by Panacela, are also included. These investments are classified as held to maturity given the intent and ability to hold the investments to maturity. Accordingly, these investments are carried at amortized cost. Unrealized gains and losses on available for-sale investments are reported as Other Comprehensive Loss, a separate component of stockholders’ equity. Realized gains and losses, and interest and dividends on available-for-sale securities are recorded in our Consolidated Statement of Operations as Interest and Other Income (Expense). The cost of securities sold is based on the specific identification method. Concentrations of Credit Risk Financial instruments that potentially subject the Company to a significant concentration of credit risk primarily consist of cash and cash equivalents and short-term investments. The Company maintains cash balances with financial institutions in excess of insured limits. As of December 31, 2017 , the Company held 3% of its cash and cash equivalents in accounts located outside of the United States. As of February 14, 2018 , the Dollar:Russian Ruble exchange rate increased from 57.6002 to 57.7701 , resulting in a decrease of $(0.3) thousand to the Company’s cash and cash equivalents as compared to December 31, 2017 . Significant Customers and Accounts Receivable The following table presents our revenue by customer, on a proportional basis, for the periods indicated: Years ended December 31, 2017 2016 Variance U.S. Department of Defense 69.0 % 35.4 % 33.6 % Russian government agencies — % 46.9 % (46.9 )% Incuron, LLC 31.0 % 17.7 % 13.3 % 100.0 % 100.0 % — % Although the Company anticipates ongoing contract and grant revenue from these customers, there is no guarantee that these revenue streams will continue in the future. The Company extends unsecured credit to its government customers under normal trade agreements and contracted terms, which generally require payment within 30 days . Accounts receivable consist of amounts due under contracts and grants from these customers, along with amounts receivable under subleases at our Buffalo, New York office facility. There were allowances for doubtful accounts of $0.2 million and $0.2 million at December 31, 2017 and December 31, 2016 , respectively, pertaining to accounts receivable from our subleases. Equipment Equipment is stated at cost, net of accumulated depreciation. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is credited or charged to operations. Repair and maintenance costs are expensed as incurred. Equipment is depreciated using the straight-line method over the estimated useful lives of the respective assets as follows: Asset Category Estimated Useful Life (in Years) Laboratory equipment 5 Furniture and fixtures 5 Computer equipment 3 Impairment of Long-Lived Assets Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amounts of the assets or related asset group may not be recoverable. Determination of recoverability is based on an estimate of discounted future cash flows resulting from the use of the asset. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the asset or asset group, the carrying amount of the asset is written down to its estimated net realizable value. Intellectual Property Costs related to filing and pursuing patent applications are recognized as general and administrative expenses as incurred, since the recoverability of such expenditures is uncertain. Upon marketability approval by the U.S. Food and Drug Administration (" FDA "), or a respective foreign regulatory governing body, such costs will be capitalized and depreciated over the expected life of the related patent. Deferred Revenue Deferred revenue represents cash received under grants and contracts in excess of the revenue recognizable through the end of the respective financial reporting period. The revenue associated with these advances will be recognized in future periods as the applicable costs are incurred. Accrued Warrant Liability Certain warrants are accounted for as derivative instruments in accordance with the Financial Accounting Standards Board Accounting Standards Codification (the " Codification ") on derivatives and hedging as the warrant holders, under certain change of control situations, could require settlement in cash. As such, the warrants were initially recorded as liabilities based on their fair values on the date of issuance. Subsequent changes in the value of the warrants are recorded in the Statements of Operations as "Change in value of warrant liability." The Company’s remaining outstanding warrants were treated as equity upon issuance and continue to be treated as equity since they did not contain any mandatory redemption features or other provisions that would require a different classification of these warrant instruments outside of permanent equity. Foreign Currency Translation The Russian ruble is the functional currency of our foreign subsidiaries, which are all located in the Russian Federation. Assets and liabilities of these companies are translated into U.S. dollars at the period-end exchange rate. Income and expense items are translated at the average exchange rates during the period. The net effect of this translation is recorded in the consolidated financial statements as accumulated other comprehensive income (loss). Other Comprehensive Income/(Loss) The Company applies the Codification on comprehensive income (loss) that requires disclosure of all components of comprehensive income (loss) on an annual and interim basis. Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. The following table presents the changes in accumulated other comprehensive loss for the year ended December 31, 2017 . Unrealized gain (loss) on available-for-sale securities Gains and losses on foreign exchange translations Total Beginning balance $ (2,286 ) $ (562,273 ) $ (564,559 ) Other comprehensive income (loss) before reclassifications 362 47,740 48,102 Ending balance $ (1,924 ) $ (514,533 ) $ (516,457 ) Revenue Recognition The Company generates grant and contract revenue from two different types of contractual arrangements: cost reimbursable grants and contracts, and fixed-price grants and contracts. Costs consist primarily of internal labor charges, subcontractors and materials, as well as an allocation of fringe benefits, overhead and general and administrative expenses, based on the terms of the contract. Under cost reimbursable grants and contracts, revenue is recognized during the period that the associated research and development costs are incurred. Under fixed-price grants and contracts, revenue is recognized using the percentage-of-completion method. The assumptions and estimates used in determination of the percentage-of-completion are developed in coordination with the principal investigator performing the work. Research and Development Research and development (" R&D ") costs are expensed as incurred. R&D costs primarily consist of salaries, fringe benefits, and stock-based compensation for our clinical and scientific personnel along with a ratable share of our facility expenses. Other R&D expenses include fees paid to research-oriented consultants and outside service providers, and the costs of materials used in clinical trials and other research activities. Accounting for Stock-Based Compensation The 2006 Equity Incentive Plan, as amended (the " Plan" ), authorizes CBLI to grant (i) options to purchase common stock, (ii) restricted or unrestricted stock units, and (iii) stock appreciation rights, so long as the exercise or grant price of each are at least equal to the fair market value of the stock on the date of grant. At the 2015 annual meeting of stockholders, an amendment to increase the maximum number of shares of common stock reserved for issuance under the Plan was approved, and as of December 31, 2017 , an aggregate of 650,000 shares of common stock were authorized for issuance under the Plan, of which a total of approximately 309,689 shares of common stock remained available for future awards. A single participant cannot be awarded more than 100,000 shares annually. Awards granted under the Plan have a contractual life of no more than 10 years . The terms and conditions of equity awards (such as price, vesting schedule, term and number of shares) under the Plan are specified in an award document, and approved by the CBLI board of directors. The Company utilizes the Black-Scholes valuation model for estimating the fair value of all stock options granted. No options were granted during the years ended December 31, 2017 and 2016. In June 2013, CBLI’s stockholders approved the 2013 Employee Stock Purchase Plan (" ESPP "), which provides a means by which eligible employees of CBLI, and certain designated related corporations, may be given an opportunity to purchase shares of CBLI common stock. As of December 31, 2017 , there were 425,000 shares of common stock reserved for purchase under the ESPP. The number of shares reserved for purchase under the ESPP increases on January 1 of each calendar year by the lesser of (i) 10% of the total number of shares of common stock outstanding on December 31 of the preceding year, or (ii) 100,000 shares of common stock. The ESPP allows employees to use up to 15% of their compensation, up to $25,000 per year, to purchase shares of common stock at an amount equal to 85% of the fair market value of the our common stock on the offering date or the purchase date, whichever is less. Income taxes No income tax expense was recorded for the years ended December 31, 2017 and 2016 , as the Company did not have taxable income for any of the years presented. A full valuation allowance has been recorded against the Company’s net deferred tax asset. Earnings (loss) per share Basic net income (loss) per share of common stock excludes dilution for potential common stock issuances and is computed by dividing net income (loss) by the weighted average number of shares outstanding for the period. Diluted net income (loss) per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. Diluted net loss per share is identical to basic net loss per share as potentially dilutive securities have been excluded from the calculation of diluted net loss per common share because the inclusion of such securities would be antidilutive. The Company has excluded the following outstanding warrants and options from the calculation of diluted net loss per share because all such securities were antidilutive for the periods presented: As of December 31, Common Equivalent Securities 2017 2016 Warrants 710,174 2,148,741 Options 211,487 233,367 Total 921,661 2,382,108 Recently Issued Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board ( "FASB" ) or other standard-setting bodies that are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption. In November 2016, the FASB issued ASU 2016-18, "Statement of Cash Flows (Topic 230): Restricted Cash" (" ASU 2016-18" ). ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. ASU 2016-18 is effective for fiscal years beginning after December 15, 2017. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2016-18 on its consolidated financial statements. In May 2016, the FASB issued ASU 2016-12, "Revenue from Contracts with Customers (Topic 606): Narrow Scope Improvements and Practical Expedients" (" ASU 2016-12" ). The amendments in ASU 2016-12 affect the guidance in ASU 2014-09 by clarifying certain specific aspects of the guidance, including assessment of collectability, treatment of sales taxes and contract modifications, and providing certain technical corrections. The pronouncement has the same effective date as ASU 2014-09, which is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2017. The Company is currently evaluating the impact of ASU 2016-12 on its consolidated financial statements. In April 2016, the FASB issued ASU 2016-10, "Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing" (" ASU 2016-10" ) related to identifying performance obligations and licensing. ASU 2016-10 is meant to clarify the guidance in FASB ASU 2014-09. Specifically, ASU 2016-10 addresses an entity’s identification of its performance obligations in a contract, as well as an entity’s evaluation of the nature of its promise to grant a license of intellectual property and whether or not that revenue is recognized over time or at a point in time. The pronouncement has the same effective date as ASU 2014-09. The Company is currently evaluating the impact of ASU 2016-10 on its consolidated financial statements. In March 2016, the FASB issued ASU 2016-09, "Improvements to Employee Share-Based Payment Accounting" (" ASU 2016-09" ). ASU 2016-09 affects entities that issue share-based payment awards to their employees. ASU 2016-09 is designed to simplify several aspects of accounting for share-based payment award transactions which include the income tax consequences, classification of awards as either equity or liabilities, classification on the statement of cash flows and forfeiture rate calculations. ASU 2016-09 is effective for annual periods beginning after December 15, 2016 and for interim periods thereafter. The Company adopted this pronouncement for the year ended December 31, 2016. In February 2016, the FASB issued ASU 2016-02, "Leases (Topic 842)" (" ASU 2016-02" ). ASU 2016-02 will require organizations that lease assets with lease terms of more than 12 months to recognize assets and liabilities for the rights and obligations created by those leases on their balance sheets. The ASU will also require new qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. ASU 2016-02 will be effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018, with early adoption permitted. The Company expects to adopt this guidance when effective and is currently evaluating the effect that the updated standard will have on its consolidated balance sheets and related disclosures. In January 2016, the FASB issued ASU 2016-01, "Financial Instruments - Overall: Recognition and Measurement of Financial Assets and Financial Liabilities" (" ASU 2016-01" ). The pronouncement requires equity investments (except those accounted for under the equity method of accounting, or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income, requires public business entities to use the exit price notion when measuring the fair value of financial instruments for disclosure purposes, requires separate presentation of financial assets and financial liabilities by measurement category and form of financial asset, and eliminates the requirement for public business entities to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost. These changes become effective for the Company’s fiscal year beginning January 1, 2018. The expected adoption method of ASU 2016-01 is being evaluated by the Company and the adoption is not expected to have a significant impact on the Company’s consolidated financial position or results of operations. In May 2014, the FASB issued Accounting Standards Update (" ASU 2014-9" ), "Revenue from Contracts with Customers," which updates the principles for recognizing revenue. ASU 2014-9 also amends the required disclosures of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. ASU 2014-9 was scheduled to be effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. In August 2015, the FASB issued ASU 2015-14, "Revenue from Contracts with Customers (Topic 606): Deferral of Effective Date" ("ASU 2015-14") which defers the effective date of ASU 2014-09 by one year. ASU 2014-9 is now effective for annual reporting periods after December 15, 2017 including interim periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. The Company is evaluating the potential impacts of the new standard on its existing revenue recognition policies and procedures. In August 2014, the FASB issued ASU 2014-15, "Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern" (" ASU 2014-15" ), which requires that an entity’s management evaluate whether there are conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. ASU 2014-15 is effective for annual periods beginning after December 15, 2016 and for interim periods thereafter. The Company adopted this pronouncement during the year ended December 31, 2016.

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2017
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The Company measures and records cash equivalents and warrant liabilities at fair value in the accompanying financial statements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability, an exit price, in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value include: • Level 1 – Observable inputs for identical assets or liabilities such as quoted prices in active markets; • Level 2 – Inputs other than quoted prices in active markets that are either directly or indirectly observable; and • Level 3 – Unobservable inputs in which little or no market data exists, which are therefore developed by the Company using estimates and assumptions that reflect those that a market participant would use. The following tables represent the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2017 and 2016 : As of December 31, 2017 Level 1 Level 2 Level 3 Total Assets: Cash and cash equivalents $ 551,088 $ — $ — $ 551,088 Short-term investments 3,606,499 954,858 — 4,561,357 Total assets $ 4,157,587 $ 954,858 $ — $ 5,112,445 Liabilities: Accrued warrant liability $ — $ — $ 1,041,455 $ 1,041,455 As of December 31, 2016 Level 1 Level 2 Level 3 Total Assets: Cash and cash equivalents $ 2,436,589 $ — $ — $ 2,436,589 Short-term investments 7,487,365 856,292 — 8,343,657 Total assets $ 9,923,954 $ 856,292 $ — $ 10,780,246 Liabilities: Accrued warrant liability $ — $ — $ 949,419 $ 949,419 Total liabilities $ — $ — $ 949,419 $ 949,419 The Company has certain warrants that could require settlement in cash if a fundamental transaction occurs, as defined in the respective agreements. These agreements specify the amount due to warrant holders is based on the Black-Scholes pricing model. The following are the assumptions used to measure the accrued warrant liability at December 31, 2017 and 2016 : "Risk-free interest rate" means the range of U.S. Treasury rates with a term that most closely resembles the expected life of the option as of the date the option is granted. "Expected dividend yield" means the anticipated dividend return for an investor over the expected life. For the Company, this amount is zero as it is not anticipated that dividends will be paid for the foreseeable future. "Expected life" means the period of time that options granted are expected to remain outstanding, based wholly on the use of the simplified (safe harbor) method. The simplified method is used because the Company does not yet have adequate historical exercise information to estimate the expected life the options granted. "Expected volatility" means a measure of the amount by which a financial variable, such as share price, has fluctuated (historical volatility) or is expected to fluctuate (implied volatility) during a period. Expected volatility is based on the Company’s historical volatility and incorporates the volatility of the common stock of comparable companies when the expected life of the option exceeds the Company’s trading history. December 31, 2017 2016 Stock Price $ 4.01 $ 1.42 Exercise Price $ 3.00 - 24.40 $ 3.00 - 60.00 Term in years 0.25 - 3.60 0.17 - 4.60 Volatility 71.48 - 139.58% 52.88 - 96.36% Annual rate of quarterly dividends 0 % 0 % Discount rate- bond equivalent yield 0.44 - 2.05% .15 - 1.84% The following table sets forth a summary of changes in the fair value of the Company’s Level 3 fair value measurement of the accrued warrant liability for the years ended December 31, 2017 and 2016 : Year Ended December 31, 2017 Beginning Balance $ 949,419 Total (gains) or losses, realized and unrealized, included in earnings (1) 4,426,146 Settlements (4,334,110 ) Balance at, December 31, 2017 $ 1,041,455 Year Ended December 31, 2016 Beginning Balance $ 4,048,900 Total (gains) or losses, realized and unrealized, included in earnings (1) (3,099,481 ) Balance at, December 31, 2016 $ 949,419 (1) Unrealized gains or losses related to the accrued warrant liability were included as change in value of accrued warrant liability. Separate disclosure is required for assets and liabilities measured at fair value on a recurring basis, as documented above, from those measured at fair value on a nonrecurring basis. As of December 31, 2017 and 2016 , the Company had no assets or liabilities that were measured at fair value on a nonrecurring basis. The Company considers the accrued warrant liability measurement to be Level 3 because some of the inputs into the measurements are neither directly or indirectly observable. The following table summarizes the unobservable inputs into the fair value measurements: December 31, 2017 Description Fair Value Valuation Technique Unobservable Input Range in years Accrued warrant liability $ 1,041,455 Black-scholes pricing model Expected term 0.25 - 3.60 Management believes the value of the accrued warrant liability is more sensitive to changes in the Company’s stock price at the end of the respective reporting period as opposed to changes in the expected term. At December 31, 2017 , a 10% increase in the expected term of the Company’s warrants measured using the Black-Scholes pricing model would increase the warrant liability by approximately 2% , while a 10% decrease in the expected term would decrease the warrant liability by approximately 2% . A 10% increase in the Company’s stock price would result in an increase in the accrued warrant liability of approximately 16% , while a 10% decrease in the stock price would decrease the warrant liability by approximately 16% . The carrying amounts of the Company’s remaining financial instruments, which include cash, short-term investments, accounts receivable and accounts payable, approximate their fair values due to their short maturities.

Equipment

Equipment	12 Months Ended
	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
Equipment	Equipment The following table summarizes the value of the Company’s equipment as of December 31, 2017 and 2016 : As of December 31, 2017 2016 Computer equipment $ 208,943 $ 205,280 Lab equipment 554,880 575,793 Furniture 500,202 500,202 1,264,025 1,281,275 Less accumulated depreciation (1,245,437 ) (1,243,899 ) Equipment, net $ 18,588 $ 37,376

Equity Awards

Equity Awards	12 Months Ended
	Dec. 31, 2017
Equity [Abstract]
Equity Awards	Warrants In connection with sales of the Company's common stock and the issuance of debt instruments that have since been repaid, warrants were issued. The warrants expire between one and seven years from issuance from the date of grant, and are subject to the terms applicable in each agreement. The following table sets forth the changes in the number of warrants outstanding for the periods presented: Number of Warrants Weighted Average Exercise Price Outstanding at December 31, 2015 2,222,155 $ 13.98 Forfeited, Canceled (73,414 ) 100.00 Outstanding at December 31, 2016 2,148,741 11.04 Exercised (1,181,235 ) 3.64 Forfeited, Canceled (257,332 ) 50.76 Outstanding at December 31, 2017 710,174 8.95 During April 2017, warrant holders exercised 1,181,235 warrants for 292,668 shares of the Company's common stock through cashless exercise. The fair value of the warrants exercised was valued using the Black Scholes option pricing model based on the following assumptions: Stock Price $ 4.84 Exercise Price $ 3.64 Term in years 4.29 Volatility 101.93 % Annual rate of quarterly dividends 0 % Discount rate- bond equivalent yield 1.65 % Equity Incentive Plan The following is a summary of option award activity under the Plan for the year ended December 31, 2017 : Year Ended December 31, 2017 Total Stock Options Outstanding Weighted Average Exercise Price per Share Nonvested Stock Options Weighted Average Grant Date Fair Value per Share December 31, 2016 233,367 $ 41.98 — $ — Granted — — — — Vested — — — — Exercised — — — — Forfeited, Canceled (21,880 ) 90.70 — — December 31, 2017 211,487 36.94 — — The following is a summary of outstanding stock options under the Plan as of December 31, 2017 : Stock Options Outstanding Vested Stock Options Quantity 211,487 211,487 Weighted-average exercise price $ 36.94 $ 36.94 Weighted Average Remaining Contractual Term (in Years) 5.26 5.26 Intrinsic value $ 65,382 $ — For the years ended December 31, 2017 and 2016 , the Company granted no stock options. For the years ended December 31, 2017 and 2016 , the total fair value of options vested was $0 , and $83,789 , respectively. The total intrinsic value of options exercised for the years ended December 31, 2017 and 2016 was $0 , and $0 , respectively. As of December 31, 2017 , there was no total compensation cost not yet recognized related to unvested stock options.

Significant Alliances and Relat

Significant Alliances and Related Parties	12 Months Ended
	Dec. 31, 2017
Related Party Transactions [Abstract]
Significant Alliances and Related Parties	Significant Alliances and Related Parties Roswell Park Cancer Institute The Company has entered into several agreements with Roswell Park Cancer Institute (" RPCI "), including: various sponsored research agreements, an exclusive license agreement and clinical trial agreements for the conduct of the Phase 1 entolimod oncology study and the Phase 1 CBL0137 intravenous administration study. Additionally, the Company’s Chief Scientific Officer, Dr. Andrei Gudkov, is the Senior Vice President of Basic Research at RPCI. The Company incurred $55,299 and $635,187 in expense to RPCI related to research grants and agreements for the years ended December 31, 2017 and 2016 , respectively. The Company had $8,391 and $91,928 included in accounts payable owed to RPCI at December 31, 2017 and 2016 , respectively. In addition, the Company had $84,429 and $110,487 in accrued expenses payable to RPCI at December 31, 2017 and 2016 , respectively. The Cleveland Clinic CBLI entered into an exclusive license agreement, or the License, with The Cleveland Clinic (" CCF "), pursuant to which CBLI was granted an exclusive license to The Cleveland Clinic’s research base underlying our therapeutic platform and certain product candidates in development by Panacela. CBLI has the primary responsibility to fund all newly developed patents; however, CCF retains ownership of those patents covered by the agreement. CBLI also agreed to use commercially diligent efforts to bring one or more products to market as soon as practical, consistent with sound and reasonable business practices and judgments. In consideration for the License, CBLI agreed to issue CCF common stock and make certain milestone, royalty and sublicense royalty payments. Milestone payments, which may be credited against future royalties, amounted to $0 , and $0 for the years ended December 31, 2017 and 2016 , respectively. No royalty or sublicense royalty payments were made to CCF during the two-year period ended December 31, 2017 . The Company also recognized $11,700 , and $0 as research and development expense to CCF for the years ended December 31, 2017 and 2016 , respectively. The Company had $11,700 and $0 included in accrued expenses payable at December 31, 2017 and 2016 , respectively. Buffalo BioLabs and Incuron Our Chief Scientific Officer, Dr. Andrei Gudkov has business relationships with several entities with which we transact business, the most significant of which is Buffalo BioLabs (" BBL "), where Dr. Gudkov was a founder and currently serves as its Principal Scientific Adviser. Pursuant to a master services agreement we have with BBL, the Company recognized $197,900 and $730,164 as research and development expense payable to BBL for the years ended December 31, 2017 and 2016 , respectively, and included $0 and $1,319 in accounts payable to BBL at December 31, 2017 and 2016 , respectively. In addition, the Company had $ 13,889 and $23,500 in accrued expenses payable to BBL at December 31, 2017 and 2016 , respectively. We also recognized $42,361 and $90,607 from BBL for sublease and other income for the years ended December 31, 2017 and 2016 , respectively. Pursuant to our real estate sublease and equipment lease with BBL, we had gross and net accounts receivable of $202,151 and $ 0 from BBL at December 31, 2017 and gross and net accounts receivables of $209,853 and $ 7,702 from BBL at December 31, 2016 , respectively. Dr. Gudkov is also an uncompensated member of the board of directors for Incuron. Pursuant to master service and development agreements we have with Incuron, the Company performs various research, business development, clinical advisory, and management services. We recognized revenue of $604,010 and $622,360 from Incuron for the years ended December 31, 2017 and 2016 , respectively. In addition, we also recognized $7,104 and $7,104 from Incuron for sublease and other income for the years ended December 31, 2017 and 2016 , respectively. Pursuant to these agreements, we had gross accounts receivable of $158,651 and $70,659 at December 31, 2017 and 2016 , respectively. Exacte Labs, LLC Our majority owned subsidiary's Chief Executive Officer also serves as the Chief Executive Officer of Exacte Labs, LLC a Contract Research Organization (" CRO ") with which BioLab 612 transacted business during 2017. BioLab 612 incurred $14,447 in expense to Exacte Labs for the year ended December 31, 2017 .

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The Company accounts for income taxes using the asset and liability method. Deferred taxes are determined by calculating the future tax consequences attributable to differences between the financial accounting and tax bases of existing assets and liabilities. A valuation allowance is recorded against deferred tax assets when, in the opinion of management, it is more likely than not that the Company will not be able to realize the benefit from its deferred tax assets. The Company files income tax returns, as prescribed by the national, state and local jurisdictions in which it operates. The Company’s uncertain tax positions are related to tax years that remain subject to examination and are recognized in the financial statements when the recognition threshold and measurement attributes are met. Interest and penalties related to tax deficiencies and uncertain tax positions are recorded as income tax expense. Income (Loss) from continuing operations consists of the following: For the Year Ended December 31, 2017 2016 US operations $ (9,315,082 ) $ (2,010,415 ) Foreign operations (527,590 ) (579,644 ) $ (9,842,672 ) $ (2,590,059 ) The provision for income taxes charged to continuing operations is $0 for all periods presented. Deferred tax assets (liabilities) were comprised of the following as of the periods presented below: As of December 31, 2017 2016 Deferred tax assets: Operating loss carryforwards $ 34,427,000 $ 50,687,000 Accrued expenses 5,969,000 8,781,000 Tax credit carryforwards 3,864,000 3,747,000 Intellectual property 3,878,000 4,097,000 Equipment 150,000 283,000 Total deferred tax assets 48,288,000 67,595,000 Deferred tax liabilities: — — Net deferred tax asset 48,288,000 67,595,000 Valuation allowance (48,288,000 ) (67,595,000 ) $ — $ — The provision for income taxes differs from the amount of income tax determined by applying the applicable U.S. statutory federal income tax rate to the pretax loss from continuing operations as a result of the following differences: For the Year Ended December 31, 2017 2016 Tax at the U.S. statutory rate $ (3,347,000 ) $ (881,000 ) Change in value of warrant liability 1,505,000 (1,054,000 ) Valuation allowance 1,841,000 1,933,000 Other 1,000 2,000 $ — $ — At December 31, 2017 , the Company had U.S. federal net operating loss carryforwards of approximately $139.7 million , which begin to expire if not utilized by 2023 , and approximately $4,046,000 of tax credit carryforwards which begin to expire if not utilized by 2024. The Company also has state net operating loss carryforwards of approximately $84.2 million , which begin to expire if not utilized by 2027 and state tax credit carryforwards of approximately $311,000 , which begin to expire if not utilized by 2022 . The purchase of 6,459,948 shares of common stock by Mr. Davidovich on July 9, 2015 resulted in Mr. Davidovich owning 60.2% of the Company, at that time. We therefore believe it highly likely that this transaction will be viewed by the U.S. Internal Revenue Service as a change of ownership as defined by Section 382 of the Internal Revenue Code. Consequently, our ability to utilize approximately $124.8 million of U.S. federal net operating loss carryforwards, $3.65 million of U.S. tax credit carryforwards, approximately $73.4 million of state net operating loss carryforwards, and $324,000 of state tax credit carryforwards, all of which occurred prior to July 9, 2015, are limited. As such, a significant portion of these carryforwards will likely expire before they can be utilized, even if the Company is able to generate taxable income that, except for this transaction, would have been sufficient to fully utilize these carryforwards. The Company files U.S. federal income tax returns, along with various state and foreign income tax returns. All federal, state and foreign tax returns for the years ended December 31, 2016 , 2015 and 2014 are still open for examination. The following presents a roll-forward of the unrecognized tax benefits and the associated interest and penalties: Unrecognized Tax Benefits Interest and Penalties Balance at January 1, 2016 $ 468,000 $ — Prior year tax position — — Current year tax position — — Deferred tax position 14,000 — Settlements with tax authorities — — Expiration of the statute of limitations — — Balance at December 31, 2016 482,000 — Prior year tax position — — Current year tax position — — Deferred tax position 11,000 — Settlements with tax authorities — — Expiration of the statute of limitations — — Balance at December 31, 2017 $ 493,000 $ — CBLI claimed New York State incentive tax credit refunds of $48,000 and $60,000 during 2017 and 2016 , respectively. These refundable tax credits were based on the Company’s research and development activities, real estate tax payments, employment levels and equipment purchases. Since there is no state tax liability or refund of prior year tax payments, these refundable tax credits were recorded against operating expenses in the year of receipt, instead of being recorded as an income tax benefit. The U.S. government enacted the Tax Cuts and Jobs Act (the "Tax Act" ) on December 22, 2017, which made several changes to U.S. tax laws that could have a significant impact on the Company. Most of these provisions are effective for tax years beginning after December 31, 2017, and include, but are not limited to, (1) a reduction in the corporate tax rate from 34% to 21%, (2) limitations on the utilization of operating loss carryforwards, (3) limitations on the utilization of interest deductions, (4) requiring a one-time transition tax on undistributed earnings of foreign subsidiaries, (5) elimination of U.S. taxes on dividends received from foreign subsidiaries, (6) implementing a base erosion tax, and (7) implementing a new provision designed to tax currently in the U.S. global intangible low-taxed income (" GILTI ") of foreign subsidiaries. U.S. GAAP requires the impact of tax legislation to be recorded in the period of enactment. Accordingly, the Company's deferred tax assets were reduced by approximately $21.5 million to reflect the lower tax rate that will apply going forward, however, there was no income tax expense given the existence of a full valuation allowance recorded against the deferred tax assets. None of the Company's foreign subsidiaries have undistributed earnings, so there is no impact associated with the one-time transition tax. Going forward, a tax liability could exist under the new GILTI provisions, but that will not apply until the foreign subsidiaries begin to generate income. The timing and amount of income to be generated by the foreign subsidiaries, and the impact of the new GILTI provision is impossible to estimate at this time, and therefore, no impact has been recorded.

Employee Benefit Plan

Employee Benefit Plan	12 Months Ended
	Dec. 31, 2017
Retirement Benefits [Abstract]
Employee Benefit Plan	Employee Benefit Plan CBLI maintains an active defined contribution retirement plan for its employees, referred to herein as the Benefit Plan. All employees satisfying certain service requirements are eligible to participate in the Benefit Plan. The Company makes matching cash contributions each payroll period, up to 4% of employees’ salaries. The Company’s expense relating to the Benefit Plan was $40,962 , and $48,334 for the years ended December 31, 2017 , and 2016 , respectively.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies The Company has entered into various agreements with third parties and certain related parties in connection with the research and development activities of its existing product candidates as well as discovery efforts on potential new product candidates. These agreements include fixed obligations to sponsor research and development activities, make minimum royalty payments for licensed patents and pay additional amounts that may be required upon the achievement of scientific, regulatory and commercial milestones, including milestones such as the submission of an IND to the FDA and the first commercial sale of the Company’s products in various countries. As of December 31, 2017 the Company is uncertain as to whether any of these contingent events will become realized. There were no milestone payments or royalties on net sales accrued for any of these agreements as of December 31, 2017 and 2016 . From time-to-time, the Company may have certain contingent liabilities that arise in the ordinary course of business. The Company accrues for liabilities when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. For all periods presented, the Company was not a party to any pending material litigation or other material legal proceedings. The Company has entered into agreements with substantially all of our employees who, if terminated by the Company without cause as described in these agreements, would be entitled to severance pay. As of December 31, 2017 , the Company had unconditional purchase obligations totaling $405,920 for goods and services, substantially all of which the Company anticipates to incur during 2018 . Capital Lease In December 2011, the Company entered into a capital lease for scientific equipment. The terms of the lease required an upfront payment and monthly payments once the lease term began in March 2012. Principal and interest payments under the capital lease obligation were $0 , and $0 during the years ended December 31, 2017 and 2016 , respectively. As of March 31, 2016, the equipment purchased pursuant to the capital lease was sold, which resulted in a one-time gain of $115,049 that was reported as Other Income in the Company's Consolidated Statement of Operations for the year ended December 31, 2016 . At the time of the sale, the accumulated depreciation for the equipment was $62,111 . Operating Leases The Company leases laboratory facilities and office facilities at various locations with expiration dates ranging from 2018 to 2019 . The Company recognizes rent expense on a straight-line basis over the term of the related operating leases. For the years ended December 31, 2017 and 2016 , total rent expense related to the Company’s operating leases was $401,455 and $388,355 , respectively. In addition, the Company has subleased some of its facilities. As of December 31, 2017 , future minimum payments under operating leases are as follows: 2018 $ 386,429 2019 191,048 2020 — Total minimum lease payments $ 577,477

Summary of Significant Accoun17

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Basis of Presentation and Consolidation	Basis of Presentation and Consolidation The accompanying consolidated financial statements include the accounts of CBLI, BioLab 612, and Panacela. All significant intercompany balances and transactions have been eliminated in consolidation. These financial statements have been prepared on the accrual basis in accordance with accounting principles generally accepted in the United States (" GAAP ").
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents Of the $4.2 million and $6.9 million of cash and cash equivalents at December 31, 2017 and December 31, 2016 , respectively, $3.6 million and $2.4 million , respectively, consisted of highly liquid investments with maturities of 90 days or less when purchased. These investments consist of investments in money market funds with commercial banks and financial institutions. As of December 31, 2017 , $114,500 of the Company’s cash and cash equivalents were held in Russian banks, of which $111,600 was denominated in rubles with the remaining $2,900 denominated in U.S. dollars.
Short-Term Investments	Short-Term Investments The Company’s short-term investments are classified as available for sale and held to maturity. Short-term investments consisted of United States Treasury securities in the amount of $3.6 million which were owned by CBLI and had maturities of less than 12 months. Accordingly, these investments are carried at fair market value. In addition, $1.0 million in certificates of deposit with maturity dates beyond three months and less than one year, and owned by Panacela, are also included. These investments are classified as held to maturity given the intent and ability to hold the investments to maturity. Accordingly, these investments are carried at amortized cost. Unrealized gains and losses on available for-sale investments are reported as Other Comprehensive Loss, a separate component of stockholders’ equity. Realized gains and losses, and interest and dividends on available-for-sale securities are recorded in our Consolidated Statement of Operations as Interest and Other Income (Expense). The cost of securities sold is based on the specific identification method.
Concentrations of Credit Risk	Concentrations of Credit Risk Financial instruments that potentially subject the Company to a significant concentration of credit risk primarily consist of cash and cash equivalents and short-term investments. The Company maintains cash balances with financial institutions in excess of insured limits.
Accounts Receivable	The Company extends unsecured credit to its government customers under normal trade agreements and contracted terms, which generally require payment within 30 days .
Equipment	Equipment Equipment is stated at cost, net of accumulated depreciation. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is credited or charged to operations. Repair and maintenance costs are expensed as incurred.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amounts of the assets or related asset group may not be recoverable. Determination of recoverability is based on an estimate of discounted future cash flows resulting from the use of the asset. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the asset or asset group, the carrying amount of the asset is written down to its estimated net realizable value.
Intellectual Property	Intellectual Property Costs related to filing and pursuing patent applications are recognized as general and administrative expenses as incurred, since the recoverability of such expenditures is uncertain. Upon marketability approval by the U.S. Food and Drug Administration (" FDA "), or a respective foreign regulatory governing body, such costs will be capitalized and depreciated over the expected life of the related patent.
Deferred Revenue	Deferred Revenue Deferred revenue represents cash received under grants and contracts in excess of the revenue recognizable through the end of the respective financial reporting period. The revenue associated with these advances will be recognized in future periods as the applicable costs are incurred.
Accrued Warrant Liability	Accrued Warrant Liability Certain warrants are accounted for as derivative instruments in accordance with the Financial Accounting Standards Board Accounting Standards Codification (the " Codification ") on derivatives and hedging as the warrant holders, under certain change of control situations, could require settlement in cash. As such, the warrants were initially recorded as liabilities based on their fair values on the date of issuance. Subsequent changes in the value of the warrants are recorded in the Statements of Operations as "Change in value of warrant liability." The Company’s remaining outstanding warrants were treated as equity upon issuance and continue to be treated as equity since they did not contain any mandatory redemption features or other provisions that would require a different classification of these warrant instruments outside of permanent equity.
Foreign Currency Translation	Foreign Currency Translation The Russian ruble is the functional currency of our foreign subsidiaries, which are all located in the Russian Federation. Assets and liabilities of these companies are translated into U.S. dollars at the period-end exchange rate. Income and expense items are translated at the average exchange rates during the period. The net effect of this translation is recorded in the consolidated financial statements as accumulated other comprehensive income (loss).
Other Comprehensive Income/(Loss)	Other Comprehensive Income/(Loss) The Company applies the Codification on comprehensive income (loss) that requires disclosure of all components of comprehensive income (loss) on an annual and interim basis. Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources.
Revenue Recognition	Revenue Recognition The Company generates grant and contract revenue from two different types of contractual arrangements: cost reimbursable grants and contracts, and fixed-price grants and contracts. Costs consist primarily of internal labor charges, subcontractors and materials, as well as an allocation of fringe benefits, overhead and general and administrative expenses, based on the terms of the contract. Under cost reimbursable grants and contracts, revenue is recognized during the period that the associated research and development costs are incurred. Under fixed-price grants and contracts, revenue is recognized using the percentage-of-completion method. The assumptions and estimates used in determination of the percentage-of-completion are developed in coordination with the principal investigator performing the work.
Research and Development	Research and Development Research and development (" R&D ") costs are expensed as incurred. R&D costs primarily consist of salaries, fringe benefits, and stock-based compensation for our clinical and scientific personnel along with a ratable share of our facility expenses. Other R&D expenses include fees paid to research-oriented consultants and outside service providers, and the costs of materials used in clinical trials and other research activities.
Accounting for Stock-Based Compensation	Accounting for Stock-Based Compensation The 2006 Equity Incentive Plan, as amended (the " Plan" ), authorizes CBLI to grant (i) options to purchase common stock, (ii) restricted or unrestricted stock units, and (iii) stock appreciation rights, so long as the exercise or grant price of each are at least equal to the fair market value of the stock on the date of grant. At the 2015 annual meeting of stockholders, an amendment to increase the maximum number of shares of common stock reserved for issuance under the Plan was approved, and as of December 31, 2017 , an aggregate of 650,000 shares of common stock were authorized for issuance under the Plan, of which a total of approximately 309,689 shares of common stock remained available for future awards. A single participant cannot be awarded more than 100,000 shares annually. Awards granted under the Plan have a contractual life of no more than 10 years . The terms and conditions of equity awards (such as price, vesting schedule, term and number of shares) under the Plan are specified in an award document, and approved by the CBLI board of directors. The Company utilizes the Black-Scholes valuation model for estimating the fair value of all stock options granted. No options were granted during the years ended December 31, 2017 and 2016. In June 2013, CBLI’s stockholders approved the 2013 Employee Stock Purchase Plan (" ESPP "), which provides a means by which eligible employees of CBLI, and certain designated related corporations, may be given an opportunity to purchase shares of CBLI common stock. As of December 31, 2017 , there were 425,000 shares of common stock reserved for purchase under the ESPP. The number of shares reserved for purchase under the ESPP increases on January 1 of each calendar year by the lesser of (i) 10% of the total number of shares of common stock outstanding on December 31 of the preceding year, or (ii) 100,000 shares of common stock. The ESPP allows employees to use up to 15% of their compensation, up to $25,000 per year, to purchase shares of common stock at an amount equal to 85% of the fair market value of the our common stock on the offering date or the purchase date, whichever is less.
Income taxes	Income taxes No income tax expense was recorded for the years ended December 31, 2017 and 2016 , as the Company did not have taxable income for any of the years presented. A full valuation allowance has been recorded against the Company’s net deferred tax asset.
Earnings (loss) per share	Earnings (loss) per share Basic net income (loss) per share of common stock excludes dilution for potential common stock issuances and is computed by dividing net income (loss) by the weighted average number of shares outstanding for the period. Diluted net income (loss) per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. Diluted net loss per share is identical to basic net loss per share as potentially dilutive securities have been excluded from the calculation of diluted net loss per common share because the inclusion of such securities would be antidilutive.
Recent Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board ( "FASB" ) or other standard-setting bodies that are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption. In November 2016, the FASB issued ASU 2016-18, "Statement of Cash Flows (Topic 230): Restricted Cash" (" ASU 2016-18" ). ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. ASU 2016-18 is effective for fiscal years beginning after December 15, 2017. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2016-18 on its consolidated financial statements. In May 2016, the FASB issued ASU 2016-12, "Revenue from Contracts with Customers (Topic 606): Narrow Scope Improvements and Practical Expedients" (" ASU 2016-12" ). The amendments in ASU 2016-12 affect the guidance in ASU 2014-09 by clarifying certain specific aspects of the guidance, including assessment of collectability, treatment of sales taxes and contract modifications, and providing certain technical corrections. The pronouncement has the same effective date as ASU 2014-09, which is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2017. The Company is currently evaluating the impact of ASU 2016-12 on its consolidated financial statements. In April 2016, the FASB issued ASU 2016-10, "Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing" (" ASU 2016-10" ) related to identifying performance obligations and licensing. ASU 2016-10 is meant to clarify the guidance in FASB ASU 2014-09. Specifically, ASU 2016-10 addresses an entity’s identification of its performance obligations in a contract, as well as an entity’s evaluation of the nature of its promise to grant a license of intellectual property and whether or not that revenue is recognized over time or at a point in time. The pronouncement has the same effective date as ASU 2014-09. The Company is currently evaluating the impact of ASU 2016-10 on its consolidated financial statements. In March 2016, the FASB issued ASU 2016-09, "Improvements to Employee Share-Based Payment Accounting" (" ASU 2016-09" ). ASU 2016-09 affects entities that issue share-based payment awards to their employees. ASU 2016-09 is designed to simplify several aspects of accounting for share-based payment award transactions which include the income tax consequences, classification of awards as either equity or liabilities, classification on the statement of cash flows and forfeiture rate calculations. ASU 2016-09 is effective for annual periods beginning after December 15, 2016 and for interim periods thereafter. The Company adopted this pronouncement for the year ended December 31, 2016. In February 2016, the FASB issued ASU 2016-02, "Leases (Topic 842)" (" ASU 2016-02" ). ASU 2016-02 will require organizations that lease assets with lease terms of more than 12 months to recognize assets and liabilities for the rights and obligations created by those leases on their balance sheets. The ASU will also require new qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. ASU 2016-02 will be effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018, with early adoption permitted. The Company expects to adopt this guidance when effective and is currently evaluating the effect that the updated standard will have on its consolidated balance sheets and related disclosures. In January 2016, the FASB issued ASU 2016-01, "Financial Instruments - Overall: Recognition and Measurement of Financial Assets and Financial Liabilities" (" ASU 2016-01" ). The pronouncement requires equity investments (except those accounted for under the equity method of accounting, or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income, requires public business entities to use the exit price notion when measuring the fair value of financial instruments for disclosure purposes, requires separate presentation of financial assets and financial liabilities by measurement category and form of financial asset, and eliminates the requirement for public business entities to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost. These changes become effective for the Company’s fiscal year beginning January 1, 2018. The expected adoption method of ASU 2016-01 is being evaluated by the Company and the adoption is not expected to have a significant impact on the Company’s consolidated financial position or results of operations. In May 2014, the FASB issued Accounting Standards Update (" ASU 2014-9" ), "Revenue from Contracts with Customers," which updates the principles for recognizing revenue. ASU 2014-9 also amends the required disclosures of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. ASU 2014-9 was scheduled to be effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. In August 2015, the FASB issued ASU 2015-14, "Revenue from Contracts with Customers (Topic 606): Deferral of Effective Date" ("ASU 2015-14") which defers the effective date of ASU 2014-09 by one year. ASU 2014-9 is now effective for annual reporting periods after December 15, 2017 including interim periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. The Company is evaluating the potential impacts of the new standard on its existing revenue recognition policies and procedures. In August 2014, the FASB issued ASU 2014-15, "Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern" (" ASU 2014-15" ), which requires that an entity’s management evaluate whether there are conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. ASU 2014-15 is effective for annual periods beginning after December 15, 2016 and for interim periods thereafter. The Company adopted this pronouncement during the year ended December 31, 2016.

Summary of Significant Accoun18

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Revenue by Customer	The following table presents our revenue by customer, on a proportional basis, for the periods indicated: Years ended December 31, 2017 2016 Variance U.S. Department of Defense 69.0 % 35.4 % 33.6 % Russian government agencies — % 46.9 % (46.9 )% Incuron, LLC 31.0 % 17.7 % 13.3 % 100.0 % 100.0 % — %
Equipment Useful Lives	Equipment is depreciated using the straight-line method over the estimated useful lives of the respective assets as follows: Asset Category Estimated Useful Life (in Years) Laboratory equipment 5 Furniture and fixtures 5 Computer equipment 3
Changes in Accumulated Other Comprehensive Income (Loss)	The following table presents the changes in accumulated other comprehensive loss for the year ended December 31, 2017 . Unrealized gain (loss) on available-for-sale securities Gains and losses on foreign exchange translations Total Beginning balance $ (2,286 ) $ (562,273 ) $ (564,559 ) Other comprehensive income (loss) before reclassifications 362 47,740 48,102 Ending balance $ (1,924 ) $ (514,533 ) $ (516,457 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The Company has excluded the following outstanding warrants and options from the calculation of diluted net loss per share because all such securities were antidilutive for the periods presented: As of December 31, Common Equivalent Securities 2017 2016 Warrants 710,174 2,148,741 Options 211,487 233,367 Total 921,661 2,382,108

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2017
Fair Value Disclosures [Abstract]
Fair Value Hierarchy for Financial Assets and Liabilities Measured on Recurring Basis	The following tables represent the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2017 and 2016 : As of December 31, 2017 Level 1 Level 2 Level 3 Total Assets: Cash and cash equivalents $ 551,088 $ — $ — $ 551,088 Short-term investments 3,606,499 954,858 — 4,561,357 Total assets $ 4,157,587 $ 954,858 $ — $ 5,112,445 Liabilities: Accrued warrant liability $ — $ — $ 1,041,455 $ 1,041,455 As of December 31, 2016 Level 1 Level 2 Level 3 Total Assets: Cash and cash equivalents $ 2,436,589 $ — $ — $ 2,436,589 Short-term investments 7,487,365 856,292 — 8,343,657 Total assets $ 9,923,954 $ 856,292 $ — $ 10,780,246 Liabilities: Accrued warrant liability $ — $ — $ 949,419 $ 949,419 Total liabilities $ — $ — $ 949,419 $ 949,419
Schedule of Share-Based Payment Award Warrant Liability Valuation Assumptions	The following are the assumptions used to measure the accrued warrant liability at December 31, 2017 and 2016 : "Risk-free interest rate" means the range of U.S. Treasury rates with a term that most closely resembles the expected life of the option as of the date the option is granted. "Expected dividend yield" means the anticipated dividend return for an investor over the expected life. For the Company, this amount is zero as it is not anticipated that dividends will be paid for the foreseeable future. "Expected life" means the period of time that options granted are expected to remain outstanding, based wholly on the use of the simplified (safe harbor) method. The simplified method is used because the Company does not yet have adequate historical exercise information to estimate the expected life the options granted. "Expected volatility" means a measure of the amount by which a financial variable, such as share price, has fluctuated (historical volatility) or is expected to fluctuate (implied volatility) during a period. Expected volatility is based on the Company’s historical volatility and incorporates the volatility of the common stock of comparable companies when the expected life of the option exceeds the Company’s trading history. December 31, 2017 2016 Stock Price $ 4.01 $ 1.42 Exercise Price $ 3.00 - 24.40 $ 3.00 - 60.00 Term in years 0.25 - 3.60 0.17 - 4.60 Volatility 71.48 - 139.58% 52.88 - 96.36% Annual rate of quarterly dividends 0 % 0 % Discount rate- bond equivalent yield 0.44 - 2.05% .15 - 1.84%
Summary of Changes in Fair Value of Company's Level 3 Fair Value Measurements	The following table sets forth a summary of changes in the fair value of the Company’s Level 3 fair value measurement of the accrued warrant liability for the years ended December 31, 2017 and 2016 : Year Ended December 31, 2017 Beginning Balance $ 949,419 Total (gains) or losses, realized and unrealized, included in earnings (1) 4,426,146 Settlements (4,334,110 ) Balance at, December 31, 2017 $ 1,041,455 Year Ended December 31, 2016 Beginning Balance $ 4,048,900 Total (gains) or losses, realized and unrealized, included in earnings (1) (3,099,481 ) Balance at, December 31, 2016 $ 949,419 (1) Unrealized gains or losses related to the accrued warrant liability were included as change in value of accrued warrant liability.
Summary of Unobservable Inputs in Fair Value Measurements	The following table summarizes the unobservable inputs into the fair value measurements: December 31, 2017 Description Fair Value Valuation Technique Unobservable Input Range in years Accrued warrant liability $ 1,041,455 Black-scholes pricing model Expected term 0.25 - 3.60

Equipment (Tables)

Equipment (Tables)	12 Months Ended
	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
Summary of Equipment	The following table summarizes the value of the Company’s equipment as of December 31, 2017 and 2016 : As of December 31, 2017 2016 Computer equipment $ 208,943 $ 205,280 Lab equipment 554,880 575,793 Furniture 500,202 500,202 1,264,025 1,281,275 Less accumulated depreciation (1,245,437 ) (1,243,899 ) Equipment, net $ 18,588 $ 37,376

Equity Awards (Tables)

Equity Awards (Tables)	12 Months Ended
	Dec. 31, 2017
Equity [Abstract]
Schedule of Changes in Warrants Outstanding	he following table sets forth the changes in the number of warrants outstanding for the periods presented: Number of Warrants Weighted Average Exercise Price Outstanding at December 31, 2015 2,222,155 $ 13.98 Forfeited, Canceled (73,414 ) 100.00 Outstanding at December 31, 2016 2,148,741 11.04 Exercised (1,181,235 ) 3.64 Forfeited, Canceled (257,332 ) 50.76 Outstanding at December 31, 2017 710,174 8.95
Assumptions Used to Measure the Fair Value of Warrants Exercised	The fair value of the warrants exercised was valued using the Black Scholes option pricing model based on the following assumptions: Stock Price $ 4.84 Exercise Price $ 3.64 Term in years 4.29 Volatility 101.93 % Annual rate of quarterly dividends 0 % Discount rate- bond equivalent yield 1.65 %
Summary of Option Award Activity	The following is a summary of option award activity under the Plan for the year ended December 31, 2017 : Year Ended December 31, 2017 Total Stock Options Outstanding Weighted Average Exercise Price per Share Nonvested Stock Options Weighted Average Grant Date Fair Value per Share December 31, 2016 233,367 $ 41.98 — $ — Granted — — — — Vested — — — — Exercised — — — — Forfeited, Canceled (21,880 ) 90.70 — — December 31, 2017 211,487 36.94 — —
Summary of Outstanding Stock Options	The following is a summary of outstanding stock options under the Plan as of December 31, 2017 : Stock Options Outstanding Vested Stock Options Quantity 211,487 211,487 Weighted-average exercise price $ 36.94 $ 36.94 Weighted Average Remaining Contractual Term (in Years) 5.26 5.26 Intrinsic value $ 65,382 $ —

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Schedule of Income (Loss) from Continuing Operations before Income Tax, Domestic and Foreign	from continuing operations consists of the following: For the Year Ended December 31, 2017 2016 US operations $ (9,315,082 ) $ (2,010,415 ) Foreign operations (527,590 ) (579,644 ) $ (9,842,672 ) $ (2,590,059 )
Schedule of Deferred Tax Assets (Liabilities)	Deferred tax assets (liabilities) were comprised of the following as of the periods presented below: As of December 31, 2017 2016 Deferred tax assets: Operating loss carryforwards $ 34,427,000 $ 50,687,000 Accrued expenses 5,969,000 8,781,000 Tax credit carryforwards 3,864,000 3,747,000 Intellectual property 3,878,000 4,097,000 Equipment 150,000 283,000 Total deferred tax assets 48,288,000 67,595,000 Deferred tax liabilities: — — Net deferred tax asset 48,288,000 67,595,000 Valuation allowance (48,288,000 ) (67,595,000 ) $ — $ —
Schedule of Effective Income Tax Rate Reconciliation	The provision for income taxes differs from the amount of income tax determined by applying the applicable U.S. statutory federal income tax rate to the pretax loss from continuing operations as a result of the following differences: For the Year Ended December 31, 2017 2016 Tax at the U.S. statutory rate $ (3,347,000 ) $ (881,000 ) Change in value of warrant liability 1,505,000 (1,054,000 ) Valuation allowance 1,841,000 1,933,000 Other 1,000 2,000 $ — $ —
Summary of Unrecognized Tax Benefits and the Associated Interest and Penalties	The following presents a roll-forward of the unrecognized tax benefits and the associated interest and penalties: Unrecognized Tax Benefits Interest and Penalties Balance at January 1, 2016 $ 468,000 $ — Prior year tax position — — Current year tax position — — Deferred tax position 14,000 — Settlements with tax authorities — — Expiration of the statute of limitations — — Balance at December 31, 2016 482,000 — Prior year tax position — — Current year tax position — — Deferred tax position 11,000 — Settlements with tax authorities — — Expiration of the statute of limitations — — Balance at December 31, 2017 $ 493,000 $ —

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Lease Payments for Operating Leases	As of December 31, 2017 , future minimum payments under operating leases are as follows: 2018 $ 386,429 2019 191,048 2020 — Total minimum lease payments $ 577,477

Description of Business (Detail

Description of Business (Detail)	12 Months Ended
	Dec. 31, 2017Subsidiary
BioLab 612
Subsidiary or Equity Method Investee [Line Items]
Number of wholly-owned subsidiaries	1

Summary of Significant Accoun25

Summary of Significant Accounting Policies - Cash and Cash Equivalents (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	$ 4,230,548	$ 6,901,816	$ 5,918,424
Cash equivalents	$ 3,600,000	$ 2,400,000
Cash and highly liquid investments maturity	90 days
Russian Federation
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	$ 114,500
Russian Rubles | Russian Federation
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	111,600
US Dollars | Russian Federation
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	$ 2,900

Summary of Significant Accoun26

Summary of Significant Accounting Policies - Short-Term Investments (Details) $ in Millions	Dec. 31, 2017USD ($)
US Treasury Securities
Net Investment Income [Line Items]
Short-term investments	$ 3.6
Certificates of Deposit
Net Investment Income [Line Items]
Short-term investments	$ 1

Summary of Significant Accoun27

Summary of Significant Accounting Policies - Concentrations of Credit Risk (Details) - USD ($)	Feb. 14, 2018	Dec. 31, 2017	Dec. 31, 2016
Product Information [Line Items]
Increase in cash and cash equivalents		$ (2,671,268)	$ 983,392
Minimum
Product Information [Line Items]
Russian Ruble : Dollar Exchange Rate		$ 57.6002
Subsequent Event
Product Information [Line Items]
Increase in cash and cash equivalents	$ (300)
Subsequent Event | Maximum
Product Information [Line Items]
Russian Ruble : Dollar Exchange Rate	$ 57.7701
Outside of the U.S. | Geographic Concentration Risk | Cash and Cash Equivalents Located Outside the US
Product Information [Line Items]
Concentration risk percentage		3.00%

Summary of Significant Accoun28

Summary of Significant Accounting Policies - Significant Customers and Accounts Receivable (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Concentration Risk [Line Items]
Allowance for doubtful accounts receivable	$ 0.2	$ 0.2
Customer Concentration Risk | Sales Revenue, Services, Net
Concentration Risk [Line Items]
Concentration risk percentage	100.00%	100.00%
Increase (decrease) in concentration risk percentage	0.00%
Customer Concentration Risk | Sales Revenue, Services, Net | U.S. Department of Defense
Concentration Risk [Line Items]
Concentration risk percentage	69.00%	35.40%
Increase (decrease) in concentration risk percentage	33.60%
Customer Concentration Risk | Sales Revenue, Services, Net | Russian government agencies
Concentration Risk [Line Items]
Concentration risk percentage	0.00%	46.90%
Increase (decrease) in concentration risk percentage	(46.90%)
Customer Concentration Risk | Sales Revenue, Services, Net | Incuron, LLC
Concentration Risk [Line Items]
Concentration risk percentage	31.00%	17.70%
Increase (decrease) in concentration risk percentage	13.30%
Customer Concentration Risk | Accounts Receivable
Concentration Risk [Line Items]
Credit term	30 days

Summary of Significant Accoun29

Summary of Significant Accounting Policies - Equipment (Detail)	12 Months Ended
	Dec. 31, 2017
Laboratory equipment
Property, Plant and Equipment [Line Items]
Estimated Useful Life (in Years)	5 years
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Estimated Useful Life (in Years)	5 years
Lab equipment
Property, Plant and Equipment [Line Items]
Estimated Useful Life (in Years)	3 years

Summary of Significant Accoun30

Summary of Significant Accounting Policies - Other Comprehensive Income/(Loss) (Details)	12 Months Ended
	Dec. 31, 2017USD ($)
AOCI Including Portion Attributable to Noncontrolling Interest [Abstract]
Beginning balance	$ (564,559)
Other comprehensive income (loss) before reclassifications	48,102
Ending balance	(516,457)
Unrealized gain (loss) on available-for-sale securities
AOCI Including Portion Attributable to Noncontrolling Interest [Abstract]
Beginning balance	(2,286)
Other comprehensive income (loss) before reclassifications	362
Ending balance	(1,924)
Gains and losses on foreign exchange translations
AOCI Including Portion Attributable to Noncontrolling Interest [Abstract]
Beginning balance	(562,273)
Other comprehensive income (loss) before reclassifications	47,740
Ending balance	$ (514,533)

Summary of Significant Accoun31

Summary of Significant Accounting Policies - Revenue Recognition (Details)	12 Months Ended
	Dec. 31, 2017Agreement
Accounting Policies [Abstract]
Number of contractual arrangement	2

Summary of Significant Accoun32

Summary of Significant Accounting Policies - Accounting for Stock-Based Compensation (Detail)	12 Months Ended
	Dec. 31, 2017USD ($)shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options grants in period (in shares)	0
2006 Equity Incentive Plan (The Plan)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock authorized under 2006 Equity Incentive Plan (in shares)	650,000
Number of authorized common stock shares (in shares)	309,689
Maximum amount of shares a single participant can be awarded annually (in shares)	100,000
Contractual life of awards granted under 2006 Equity Incentive Plan	10 years
2013 ESPP Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of authorized common stock shares (in shares)	425,000
Percentage of the total number of shares of common stock outstanding of the preceding year	10.00%
Maximum amount of shares of common stock that employee can purchase per year (in shares)	100,000
Maximum percentage of annual compensation that employee can use to purchase common stock shares	15.00%
Maximum amount employee can spend to purchase common stock shares | $	$ 25,000
Percent of fair maket value that common stock can be purchased at	85.00%

Summary of Significant Accoun33

Summary of Significant Accounting Policies - Income taxes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2013
Accounting Policies [Abstract]
Income tax expense	$ 0	$ 0	$ 0

Summary of Significant Accoun34

Summary of Significant Accounting Policies - Earnings/(loss) per share (Detail) - shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common Equivalent Securities	921,661	2,382,108
Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common Equivalent Securities	211,487	233,367
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common Equivalent Securities	710,174	2,148,741

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value Hierarchy for Financial Assets and Liabilities Measured on Recurring Basis (Detail) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Liabilities:
Accrued warrant liability	$ 1,041,455	$ 949,419
Recurring
Assets:
Cash and cash equivalents	551,088	2,436,589
Short-term investments	4,561,357	8,343,657
Assets:	5,112,445	10,780,246
Liabilities:
Total liabilities		949,419
Recurring | Level 1
Assets:
Cash and cash equivalents	551,088	2,436,589
Short-term investments	3,606,499	7,487,365
Assets:	4,157,587	9,923,954
Liabilities:
Total liabilities		0
Recurring | Level 2
Assets:
Cash and cash equivalents	0	0
Short-term investments	954,858	856,292
Assets:	954,858	856,292
Liabilities:
Total liabilities		0
Recurring | Level 3
Assets:
Cash and cash equivalents	0	0
Short-term investments	0	0
Assets:	0	0
Liabilities:
Total liabilities		949,419
Warrants | Recurring
Liabilities:
Accrued warrant liability	1,041,455	949,419
Warrants | Recurring | Level 1
Liabilities:
Accrued warrant liability	0	0
Warrants | Recurring | Level 2
Liabilities:
Accrued warrant liability	0	0
Warrants | Recurring | Level 3
Liabilities:
Accrued warrant liability	$ 1,041,455	$ 949,419

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Share-Based Payment Award Warrant Liability Valuation Assumptions (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Stock price (in dollars per share)	$ 4.01	$ 1.42
Annual rate of quarterly dividends	0.00%	0.00%
Minimum
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Exercise price (in dollars per share)	$ 3	$ 3
Term in years	3 months	2 months
Volatility	71.48%	53.00%
Discount rate-bond equivalent yield	0.44%	0.15%
Maximum
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Exercise price (in dollars per share)	$ 24.4	$ 60
Term in years	3 years 7 months 5 days	4 years 7 months 5 days
Volatility	139.58%	96.36%
Discount rate-bond equivalent yield	2.05%	1.84%

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Changes in Fair Value of Company's Level 3 Fair Value Measurements (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Asset and liabilities measured at fair value on nonrecurring basis	$ 0	$ 0
Accrued Warrant Liability
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	949,419
Total (gains) or losses, realized and unrealized, included in earnings	4,426,146	(3,099,481)
Settlements	(4,334,110)
Ending balance	$ 1,041,455	$ 949,419

Fair Value Measurements - Sum38

Fair Value Measurements - Summary of Unobservable Inputs into Fair Value Measurement for Accrued Warrant Liability (Detail) - Accrued Warrant Liability - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2014
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Fair Value	$ 1,041,455	$ 949,419	$ 4,048,900
Valuation Technique	Black-scholes pricing model
Unobservable Input	Expected term
Percentage increase in expected term	10.00%
Percentage increase in warrant liability with increase in expected term	2.00%
Percentage decrease in expected term	10.00%
Percentage decrease in warrant liability with decrease in expected term	2.00%
Percentage increase in stock price	10.00%
Percentage increase in warrant liability with increase in stock price	16.00%
Percentage decrease in stock price	10.00%
Percentage decrease in warrant liability with decrease in stock price	16.00%
Minimum
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Range in years	3 months
Maximum
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Range in years	3 years 7 months 5 days

Equipment (Details)

Equipment (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Property, plant, and equipment	$ 1,264,025	$ 1,281,275
Less accumulated depreciation	(1,245,437)	(1,243,899)
Equipment, net	18,588	37,376
Computer equipment
Property, Plant and Equipment [Line Items]
Property, plant, and equipment	208,943	205,280
Lab equipment
Property, Plant and Equipment [Line Items]
Property, plant, and equipment	554,880	575,793
Furniture
Property, Plant and Equipment [Line Items]
Property, plant, and equipment	$ 500,202	$ 500,202

Equity Awards - Schedule of Cha

Equity Awards - Schedule of Changes in Warrants Outstanding (Detail) - Warrants - $ / shares	1 Months Ended	6 Months Ended	12 Months Ended
	Apr. 30, 2017	Jun. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Number of Warrants:
Number of Warrants Outstanding, Beginning balance (in shares)		2,148,741	2,148,741	2,222,155
Number of Warrants, Exercised (in shares)	(1,181,235)		(1,181,235)
Number of Warrants, Forfeited, Canceled (in shares)			(257,332)	(73,414)
Number of Warrants Outstanding, Ending balance (in shares)			710,174	2,148,741
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Weighted Average Exercise Price, Outstanding, Beginning balance (in dollars per share)		$ 11.04	$ 11.04	$ 13.98
Weighted Average Exercise Price, Forfeited, Canceled (in dollars per share)			50.76	100
Weighted Average Exercise Price, Exercised (in dollars per share)			3.64
Weighted Average Exercise Price, Outstanding, Ending balance (in dollars per share)			$ 8.95	$ 11.04
Minimum
Class of Warrant or Right [Line Items]
Warrant expiration period		1 year
Maximum
Class of Warrant or Right [Line Items]
Warrant expiration period		7 years

Equity Awards - Fair Value of W

Equity Awards - Fair Value of Warrants Exercised Using Black Scholes Option Pricing Model (Details) - $ / shares	Apr. 20, 2017	Apr. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock price (in dollars per share)			$ 4.01	$ 1.42
Expected dividend yield			0.00%	0.00%
Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock Issued through cashless exercise		292,668
Warrants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants exercised (in shares)		1,181,235	1,181,235
Stock price (in dollars per share)	$ 4.84
Exercise price (in dollars per share)	$ 3.64
Term in years	4 years 3 months 15 days
Expected volatility	101.93%
Expected dividend yield	0.00%
Risk-free interest rate	1.65%

Equity Awards - Summary of Opti

Equity Awards - Summary of Option Award Activity (Detail)	12 Months Ended
	Dec. 31, 2017$ / sharesshares
Total Stock Options Outstanding:
Total Stock Options Outstanding, Beginning balance (in shares)	233,367
Options grants in period (in shares)	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Outstanding Number of Shares	0
Total Stock Options Outstanding, Exercised (in shares)	0
Total Stock Options Outstanding, Forfeited, Canceled (in shares)	(21,880)
Total Stock Options Outstanding, Ending balance (in shares)	211,487
Weighted Average Exercise Price per Share:
Weighted Average Exercise Price per Share, Beginning balance (in dollars per share) | $ / shares	$ 41.98
Weighted Average Exercise Price per Share, Granted (in dollars per share) | $ / shares	0
Weighted Average Exercise Price Per Share, Vested | $ / shares	0
Weighted Average Exercise Price per Share, Exercised (in dollars per share) | $ / shares	0
Weighted Average Exercise Price per Share, Forfeited, Canceled (in dollars per share) | $ / shares	90.70
Weighted Average Exercise Price per Share, Ending balance (in dollars per share) | $ / shares	$ 36.94
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Exercised, Weighted Average Grant Date Fair VAlue	0
Nonvested Stock Options:
Nonvested Stock Options, Beginning balance (in shares)	0
Nonvested Stock Options, Granted (in shares)	0
Nonvested Stock Options, Vested (in shares)	0
Nonvested Stock Options, Exercised (in shares)	0
Nonvested Stock Options, Forfeited, Canceled (in shares)	0
Nonvested Stock Options, Ending balance (in shares)	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Weighted Average Grant Date Fair Value per Share, Beginning balance (in dollars per share) | $ / shares	$ 0
Weighted Average Grant Date Fair Value per Share, Granted (in dollars per share) | $ / shares	0
Weighted Average Grant Date Fair Value per Share, Vested (in dollars per share) | $ / shares	0
Weighted Average Grant Date Fair Value per Share, Forfeited, Canceled (in dollars per share) | $ / shares	0
Weighted Average Grant Date Fair Value per Share, Ending balance (in dollars per share) | $ / shares	$ 0

Equity Awards - Summary of Outs

Equity Awards - Summary of Outstanding Stock Options (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Options Outstanding, Quantity (in shares)	211,487	233,367
Stock Options Outstanding, Weighted-average exercise price (in dollars per share)	$ 36.94	$ 41.98
Options Additional Information:
Options grants in period (in shares)	0
Options vested in period, fair value	$ 0	$ 83,789
Options exercised in period intrinsic value	$ 0	$ 0
Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Options Outstanding, Quantity (in shares)	211,487
Stock Options Outstanding, Weighted-average exercise price (in dollars per share)	$ 36.94
Stock Options Outstanding, Weighted Average Remaining Contractual Term (in Years)	5 years 3 months 5 days
Stock Options Outstanding, Intrinsic value	$ 65,382
Nonvested Stock Options, Quantity (in shares)	211,487
Nonvested Stock Options, Weighted-average exercise price (in dollars per share)	$ 36.94
Nonvested Stock Options, Weighted Average Remaining Contractual Term (in Years)	5 years 3 months 5 days
Nonvested Stock Options, Intrinsic value	$ 0
Options Additional Information:
Options grants in period (in shares)	0	0
Compensation cost not yet recognized related to non-vested stock options	$ 0

Significant Alliances and Rel44

Significant Alliances and Related Parties (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Related Party Transaction [Line Items]
Research and development expense	$ 5,048,423	$ 6,496,122
R P C I
Related Party Transaction [Line Items]
Expense related to research grants and agreements	55,299	635,187
Accounts payable owed	8,391	91,928
Accrued expenses payable	84,429	110,487
Cleveland Clinic
Related Party Transaction [Line Items]
Accrued expenses payable	11,700	0
Milestone payments credited against future royalties	0	0
Royalty or sublicense royalty payments	0
Research and development expense	11,700	0
Buffalo BioLabs
Related Party Transaction [Line Items]
Accounts payable owed	0	1,319
Accrued expenses payable	13,889	23,500
Research and development expense	197,900	730,164
Accounts receivable related parties, gross	202,151	209,853
Accounts receivable related parties	0	7,702
Buffalo BioLabs | Sublease and Other Income
Related Party Transaction [Line Items]
Sublease and other income from BBL	42,361	90,607
Incuron, LLC
Related Party Transaction [Line Items]
Sublease and other income from BBL	604,010	622,360
Accounts receivable related parties, gross	158,651	70,659
Incuron, LLC | Sublease and Other Income
Related Party Transaction [Line Items]
Sublease and other income from BBL	7,104	$ 7,104
Exacte Labs, LLC
Related Party Transaction [Line Items]
Accrued expenses payable	$ 14,447

Income Taxes - Schedule of Inco

Income Taxes - Schedule of Income (Loss) from Continuing Operations before Income Tax, Domestic and Foreign (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest [Abstract]
US operations	$ (9,315,082)	$ (2,010,415)
Foreign operations	(527,590)	(579,644)
Total	$ (9,842,672)	$ (2,590,059)

Income Taxes - Additional infor

Income Taxes - Additional information (Detail) - USD ($)	Jul. 09, 2015	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Income tax expense (benefit)		$ 0	$ 0	$ 0
Operating Loss Carryforwards [Line Items]
Tax Cuts And Jobs Act, Change in Tax Rate, deferred tax assets, decrease		21,500,000
Tax Cuts And Jobs Act Of 2017, provisional income tax expense		0
Investor
Operating Loss Carryforwards [Line Items]
Stock issued during period (in shares)	6,459,948
Investor ownership percentage of company	60.20%
U.S. federal
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards		139,700,000
Tax credit carryforward		4,046,000
Operating loss carryforward limitations on use		124,800,000
Tax credit carryforward limitiations on use		3,650,000
New York
Operating Loss Carryforwards [Line Items]
Proceeds from income tax refunds		48,000	$ 60,000
State and Local Jurisdiction
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards		84,200,000
Tax credit carryforward		311,000
Operating loss carryforward limitations on use		73,400,000
Tax credit carryforward limitiations on use		$ 324,000

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets (Liabilities) (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Deferred tax assets:
Operating loss carryforwards	$ 34,427	$ 50,687
Accrued expenses	5,969	8,781
Tax credit carryforwards	3,864	3,747
Intellectual property	3,878	4,097
Equipment	150	283
Total deferred tax assets	48,288	67,595
Deferred tax liabilities:	0	0
Net deferred tax asset	48,288	67,595
Valuation allowance	(48,288)	(67,595)
Net deferred tax asset	$ 0	$ 0

Income Taxes - Schedule of Effe

Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2013
Effective Income Tax Rate Reconciliation, Amount [Abstract]
Tax at the U.S. statutory rate	$ (3,347,000)	$ (881,000)
Change in value of warrant liability	1,505,000	(1,054,000)
Valuation allowance	1,841,000	1,933,000
Other	1,000	2,000
Total	$ 0	$ 0	$ 0

Income Taxes - Summary of Unrec

Income Taxes - Summary of Unrecognized Tax Benefits and the Associated Interest and Penalties (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Unrecognized Tax Benefits
Beginning balance, Unrecognized tax benefits	$ 482,000	$ 468,000
Prior year tax position	0	0
Current year tax position	0	0
Deferred tax position	11,000	14,000
Settlements with tax authorities	0	0
Expiration of the statute of limitations	0	0
Ending balance, Unrecognized tax benefits	493,000	482,000
Interest and Penalties
Beginning balance, Interest and penalties	0	0
Prior year tax position	0	0
Current year tax position	0	0
Deferred tax position	0	0
Settlements with tax authorities	0	0
Expiration of the statute of limitations	0	0
Ending balance at December, Interest and penalties	$ 0	$ 0

Employee Benefit Plan (Detail)

Employee Benefit Plan (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Retirement Benefits [Abstract]
Maximum percentage of employees' paycheck that company matches	4.00%
Expense relating to the Benefit Plan	$ 40,962	$ 48,334

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - USD ($)	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Milestone payment & royalties		$ 0	$ 0
Unconditional purchase obligation		405,920
Debt instrument, periodic payment		0	0
Gain on equipment disposal	$ 115,049	6,727	180,901
Accumulated depreciation for leased equipment			62,111
Operating leases, rent expense		$ 401,455	$ 388,355

Commitments and Contingencies52

Commitments and Contingencies - Schedule of Future Minimum Lease Payments for Operating Leases (Detail)	Dec. 31, 2017USD ($)
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
2,018	$ 386,429
2,019	191,048
2,020	0
Total minimum lease payments	$ 577,477